- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06189313
CLEANer Aspiration for Pulmonary Embolism (CLEAN-PE)
April 8, 2024 updated by: Argon Medical Devices
A Prospective, Multicenter Study to Evaluate the Safety and Efficacy of an Aspiration Thrombectomy System in Acute Pulmonary Embolism
To evaluate the safety and efficacy of the Cleaner™ Pro Thrombectomy System for aspiration thrombectomy in patients with acute pulmonary embolism (PE).
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
125
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Danyel C Carr, MS
- Phone Number: 4697311421
- Email: Clinical@argonmedical.com
Study Contact Backup
- Name: Holly Harrison
- Phone Number: 4697313561
Study Locations
-
-
South Dakota
-
Dakota Dunes, South Dakota, United States, 57049
- Vascular and Interventional Specialists of Siouxland
-
Contact:
- Nikolas Arvis, MD
- Phone Number: 605-217-7751
-
Principal Investigator:
- Neal Khurana, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- At least 18 years of age at the time of consent
- Clinical signs, symptoms, and presentation consistent with acute PE
- Onset of PE symptoms occurred within 14 days of presentation
- Filling defect in at least one main or lobar pulmonary artery evidenced by CTA
- RV dysfunction on CTA or echocardiography defined as RV/LV ratio >0.9
Exclusion Criteria:
- tPA use within 14 days prior to baseline CTA
- Systolic BP <90 mmHg for 15 min or the requirement of inotropic support to maintain systolic BP ≥90 mmHg
- Diagnosis of pulmonary hypertension or suspected undiagnosed pulmonary hypertension with peak PA >70 mmHg by right heart catheterization or elevated main pulmonary artery to aorta ratio (MPA:A)
- History of severe or chronic pulmonary hypertension
- FiO2 requirement >40% or >6 LPM to keep oxygen saturations >90%
- Hematocrit <28%
- Platelets <100,000/µL
- Serum creatinine >1.8 mg/dL
- INR >3
- aPTT (or PTT) >50 seconds on no anticoagulation
- History of heparin-induced thrombocytopenia (HIT)
- Recent (within six months) history of stroke, transient ischemic attack (TIA), or intracranial bleeding
- Recent (within one month) history of active bleeding from a major organ
- Absolute contraindication to anticoagulation
- Major trauma such as head trauma, or other active intracranial, or intraspinal disease within 14 days
- Morbidly obese (BMI >45 kg/m2) patient who by the judgement of the investigator is high risk for bleeding
- Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months
- Cardiovascular or pulmonary surgery within last 7 days
- Cancer which requires active chemotherapy
- Known serious, uncontrolled sensitivity to radiographic agents
- Life expectancy <90 days, as determined by investigator
- Female who is pregnant
- Intracardiac thrombus
- Patients who present with cardiac arrest and/or are on extracorporeal membrane oxygenation (ECMO) or ECMO required to perform interventional procedure
- Simultaneous participation in another investigational study
- Patients with known coagulation disorders such as antiphospholipid, Protein C, and Protein S
- Presentation of PE with paradoxical emboli which may be diagnosed by concurrent stroke or concurrent arterialization
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mechanical Thrombectomy via Cleaner Pro
Participants will receive catheter-directed therapy via mechanical aspiration thrombectomy for the treatment of pulmonary embolism (PE) using the Cleaner Pro Thrombectomy System.
|
The Cleaner™ Pro Thrombectomy System ("Cleaner Pro") is a catheter-based aspiration thrombectomy device comprised of a handpiece, an aspiration catheter, a dilator, and an aspiration canister.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Right Ventricle (RV)/Left Ventricle (LV) Ratio
Time Frame: At 48 hours post-procedure
|
Change in RV/LV ratio between baseline and 48 hours post procedure assessed by CTA.
|
At 48 hours post-procedure
|
Rate of Major Adverse Events (MAEs)
Time Frame: At 48 hours post-procedure
|
Rate of MAEs within the first 48 hours after the index procedure, defined as: Device-related death Major bleeding, and Device-related Serious Adverse Events which includes clinical deterioration, pulmonary vascular injury, and cardiac injury. |
At 48 hours post-procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of device-related complications and device-related death
Time Frame: Within 48 hours of the procedure
|
Rate of device-related complications including major bleeding, clinical deterioration, pulmonary vascular injury, and cardiac injury, and device-related death within 48 hours of the index procedure.
|
Within 48 hours of the procedure
|
Rate of device-related SAEs and all-cause mortality
Time Frame: Within 30 days of procedure
|
Rate of device-related serious adverse events (SAEs) and death for any cause within 30 days post-procedure.
|
Within 30 days of procedure
|
Use of thrombolytics
Time Frame: Within 48 hours of the procedure
|
Use of thrombolytics within 48 hours of the procedure.
|
Within 48 hours of the procedure
|
Change in Modified Miller Index
Time Frame: At 48 hours post-procedure
|
Change in Modified Miller Index between baseline and 48 hours post-procedure assessed by CTA.
This index score quantifies arterial obstruction in pulmonary embolism.
The higher the score, the more perfusion is reduced.
|
At 48 hours post-procedure
|
Quality of Life assessed via PEmb-QoL
Time Frame: At 30 days post-procedure
|
Self-assessment of PE-related complaints and daily living limitations (including work and social).
The PEmb-QoL measures 6 dimensions, with higher scores being worse.
|
At 30 days post-procedure
|
Quality of Life assessed via EQ-5D-5L
Time Frame: At 30 days post-procedure
|
Self-assessment of activities for daily living.
The EQ-5D-5L measures 5 dimensions, with higher scores being worse.
|
At 30 days post-procedure
|
Rate of Symptomatic PE Recurrence
Time Frame: Within 30 days of the procedure
|
Rate of Symptomatic PE recurrence within 30 days.
|
Within 30 days of the procedure
|
Volume of blood aspirated
Time Frame: At index procedure
|
The amount of blood aspirated during the procedure.
|
At index procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Danyel C Carr, MS, Argon Medical Devices
- Study Director: Pete J Stibbs, MD, Argon Medical Devices
- Principal Investigator: Aravinda Nanjundappa, MD, The Cleveland Clinic
- Principal Investigator: Neal Khurana, MD, Vascular and Interventional Specialists of Siouxland
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 23, 2024
Primary Completion (Estimated)
May 18, 2025
Study Completion (Estimated)
June 24, 2025
Study Registration Dates
First Submitted
December 19, 2023
First Submitted That Met QC Criteria
December 19, 2023
First Posted (Actual)
January 3, 2024
Study Record Updates
Last Update Posted (Actual)
April 9, 2024
Last Update Submitted That Met QC Criteria
April 8, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CNPE01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinActive, not recruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on Cleaner Pro Thrombectomy System
-
Paul J. GagneRecruitingAcute Deep Venous Thrombosis of Ileofemoral VeinUnited States
-
SurModics, Inc.RecruitingPeripheral Arterial Disease | Acute Limb IschemiaUnited States
-
RapidPulse, IncNot yet recruiting
-
RapidPulse, IncNot yet recruitingStroke | Acute Ischemic Stroke | Large Vessel Occlusion | Mechanical ThrombectomyGeorgia
-
Careggi HospitalCardiovascular Research Foundation, New YorkCompletedST-segment Elevation Myocardial Infarction | ThrombusItaly
-
Innova Vascular, Inc.Not yet recruitingPulmonary Embolism
-
MIVI Neuroscience, Inc.Active, not recruitingAcute Ischemic StrokeFrance
-
Medtronic EndovascularTerminatedArteriovenous Graft ThrombosisCanada
-
Medtronic EndovascularTerminated
-
Abbott Medical DevicesRecruitingPeripheral Artery Thrombosis | Peripheral Venous ThrombosisUnited States, Germany